William D. Tap, MD, discusses results from a phase Ib/II presented at the 2015 Connective Tissue Oncology Society (CTOS) Annual Meeting.
William D. Tap, MD, chief, Sarcoma Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses results from a phase Ib/II presented at the 2015 Connective Tissue Oncology Society (CTOS) Annual Meeting.
This study looked at the combination of olaratumab and doxorubicin compared with doxorubicin alone as treatment for patients with advanced soft tissue sarcoma. The combination showed a 50% improvement in progression-free survival and an 11.8-month increase in overall survival.
Based on this study, the monoclonal antibody is being investigated in an ongoing phase III study and has received an FDA Breakthrough Therapy Designation.
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More